Global pharmaceutical major Pfizer has been fined a record $107 million (over ₹720 crore) by UK’s competition regulator for its role in pushing up the cost of an anti-epilepsy drug by up to 2,600%. The Competition and Markets Authority, issuing its biggest fine, said the “extraordinary price rises have cost the NHS (National Health Service)... tens of millions of pounds”.